RU-58841: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 6 sources cited
Overview
RU-58841 is a non-steroidal anti-androgen developed for topical treatment of androgenetic alopecia (male pattern baldness). It works by competitively binding to androgen receptors in the scalp, blocking the hair-miniaturizing effects of dihydrotestosterone (DHT); in animal studies it did so without systemic anti-androgenic effects. Though never brought to market, it remains one of the most discussed experimental hair loss treatments in the research community.
Mechanism of Action
RU-58841 is a topical anti-androgen that competitively binds to the androgen receptor (AR) in hair follicle dermal papilla cells. DHT, converted from testosterone by 5-alpha-reductase, binds to these receptors and triggers a cascade of gene expression changes that shrink the hair follicle over successive growth cycles — a process called follicular miniaturization. RU-58841 occupies the AR binding site without activating the receptor's transcriptional activity, effectively acting as a silent blocker. Unlike systemic anti-androgens like finasteride (which inhibits DHT production) or spironolactone (which blocks AR systemically), RU-58841 is designed for topical application, limiting its activity to the scalp. In rats it is cleared from plasma quickly (half-life of about 1 hour), although a 2026 study in six men found measurable drug in blood after a single scalp application. In preclinical studies on stumptail macaques — a primate model that naturally develops pattern baldness — topical RU-58841 increased hair density, thickness and length.
RU-58841 Benefits: What the Research Shows
- A 1998 study in the journal Endocrine showed topical RU-58841 produced a marked increase in hair density, thickness and length in the bald scalp of stumptail macaques, with no systemic effects detected
- In human balding scalp grafts kept on testosterone-treated mice, topical 1% RU-58841 raised the share of follicles starting a second hair cycle (28% versus 7%) and increased hair growth rate (British Journal of Dermatology, 1997)
- In vitro studies demonstrate high binding affinity for the androgen receptor with negligible agonist activity
- Anecdotal reports from the hair loss community suggest visible thickening within 3–6 months of consistent use
- No published human trials of efficacy or safety exist; the only human study is a 2026 single-dose metabolism study in six men, so the evidence for hair growth is preclinical
RU-58841 Dosage
- Common research dose: 50 mg/mL solution applied topically to the scalp once daily
- Typical application volume: 1–2 mL per day (50–100 mg total)
- Dissolve in a vehicle of 70% ethanol / 30% propylene glycol for optimal penetration
- Apply to dry scalp, focusing on areas of thinning, ideally at bedtime
- Cycle: used continuously; effects may reverse upon discontinuation
- Some protocols alternate with minoxidil (RU-58841 at night, minoxidil in the morning)
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
RU-58841 Side Effects & Safety
Known Side Effects
- Scalp irritation, dryness, or flaking at the application site (common with alcohol-based vehicles)
- Contact dermatitis in individuals sensitive to the compound or vehicle ingredients
- Possible systemic anti-androgenic effects (reduced libido, erectile dysfunction): a 2026 study detected the drug in blood after a single scalp application, and no human trial has measured how often such effects occur
- Initial shedding ('dread shed') in the first 2–4 weeks as dormant follicles re-enter the growth cycle
- Long-term safety in humans is unknown due to lack of clinical trials
Safety Profile
RU-58841 was never approved for human use and has no published human clinical trials of efficacy or safety. The primary safety concern is potential systemic absorption leading to anti-androgenic side effects, and a 2026 study in six men found measurable drug in blood after a single scalp application. Its rapid clearance from plasma (half-life of about 1 hour) was measured in rats. Preclinical toxicology in the macaque model showed no significant systemic effects at topical doses. However, the compound is typically sourced from research chemical suppliers without pharmaceutical-grade quality control, introducing purity and contamination risks. Users should exercise caution with concentration and application area. It should not be used by women of childbearing potential due to theoretical teratogenic risks of anti-androgens. Liver and kidney function have not been formally assessed in human users.
What to Expect
Week 1–4: No visible changes. Some users experience an initial shedding phase as miniaturized hairs are pushed out by new growth. This is a positive sign but can be alarming. Week 4–8: Shedding typically resolves. Hair may feel slightly thicker at the base but no visible regrowth yet. Week 8–16: Gradual thickening of existing hairs becomes noticeable. Vellus (fine, unpigmented) hairs may appear in thinning areas. Week 16–24: More significant improvement in hair density and thickness. Best results are seen in early-stage thinning; advanced baldness responds less robustly. Ongoing: Continuous use is required to maintain results. Discontinuation leads to gradual reversal over 3–6 months.
Common Stacks
Storage & Handling
Store raw RU-58841 powder in a sealed container at -20°C, protected from light and moisture, for long-term stability (2+ years). Pre-mixed solutions in ethanol/propylene glycol should be stored at 2–8°C and used within 3 months. The compound is sensitive to heat and moisture degradation. Do not use if the solution develops discoloration or precipitate.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Battmann T, Bonfils A, Branche C, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol. 1994.
- Pan HJ, Wilding G, Uno H, et al. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 1998.
- De Brouwer B, Tételin C, Leroy T, et al. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. Br J Dermatol. 1997.
- Obana N, Chang C, Uno H. Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque. Endocrinology. 1997.
- Cousty-Berlin D, Bergaud B, Bruyant MC, et al. Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. J Steroid Biochem Mol Biol. 1994.
- Okutan A, Krug O, Fußhöller G, et al. Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans. Biomed Chromatogr. 2026.
Related Peptides
Track RU-58841 in Your Protocol
Log your RU-58841 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free